PARP1 and ovarian carcinoma: In line with these findings, in the multinational, phase 3 NOVA trial in HGSOC patients with platinum-sensitive, recurrent ovarian cancer, Niraparib, a highly-selective, potent PARP1 and PARP2 inhibitor, significantly prolonged median progression-free survival, irrespective of the presence or absence of a germline BRCA mutation and irrespective also of the presence or absence of homologous recombination repair deficiency [43].